Dozens of trials on HIV ground to a halt in February after US President Donald Trump abruptly pulled crucial funding.

GILD is trading down after disappointing first-quarter results. While the fundamentals look solid in the long run, the ...

An ambitious plan to stop the global threat of AIDS has been derailed. But many are hopeful that progress can be salvaged.

The FDA is expected to decide on treatments for bullous pemphigoid, hereditary angioedema, HIV PrEP, ovarian cancer, and RSV.

Gilead Sciences has agreed to pay USD 202 million to settle a whistleblower lawsuit that accused the company of engaging in ...

Gilead Sciences has refiled for FDA approval of its HIV capsid inhibitor lenacapavir – which only needs to be dosed every six months – after the drug was rejected by the regulator in February.

It is the first time that a PrEP trial has been shown to prevent any HIV infections from slipping through the net, according to Gilead, and showed a subcutaneous injection with lenacapavir every ...

This makes Lenacapavir significantly more ... Sub-Saharan Africa Leads Global HIV Decline Nov. 25, 2024 — A new study reveals significant progress in the global fight against HIV/AIDS ...

If all of its National Institutes of Health funding falls away, the country could lose 70% of its medical research capacity ...

Altesa BioSciences, Inc., a clinical-stage pharmaceutical company developing new treatments for viral infections in vulnerable populations, today announced the appointment of Katharine Knobil, M.D. as ...